Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2SPH4
|
|||
| Drug Name |
IW-1701
|
|||
| Synonyms |
Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Sickle-cell disorder [ICD-11: 3A51; ICD-10: D57, D57.8; ICD-9: 282.5, 282.6] | Phase 2 | [1] | |
| Company |
Cyclerion Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H16F5N7O3
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)CN2C(=CC(=N2)C3=NC=C(C(=N3)NCC(C(=O)N)(C(F)(F)F)O)F)C4=NOC=C4)F
|
|||
| InChI |
1S/C21H16F5N7O3/c22-12-4-2-1-3-11(12)9-33-16(14-5-6-36-32-14)7-15(31-33)18-28-8-13(23)17(30-18)29-10-20(35,19(27)34)21(24,25)26/h1-8,35H,9-10H2,(H2,27,34)(H,28,29,30)/t20-/m1/s1
|
|||
| InChIKey |
YWQFJNWMWZMXRW-HXUWFJFHSA-N
|
|||
| CAS Number |
CAS 1628732-62-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Guanylate cyclase (GC) | Target Info | Stimulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03285178) A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Cyclerion Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.